Mutabilis will present EBL-1463 at the 2021 BioInfect Conference Digital Event – Thursday 22nd April 2021 in the ‘What’s in the Pipeline – Part 1’ session. Title of the talk : Discovery of EBL-1463 a novel-class PBP inhibitor impervious to b-lactamase hydrolysis
READ MORECARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.
READ MORESeptember 2020. Due to the Covid-19 restrictions the 2020 AMR conference had to be held on the Internet this year. Within the session dedicated to the presentation of the IMI-ENABLE’s results, François Moreau, Mutabilis’ CSO, gave a presentation on EBL-1463. The presentation can be viewed here.
READ MOREJanuary 6th 2020: Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis to accelerate its 2G Dabocins program
READ MORETitle of the talk : DISCOVERY OF DABOCINS, A NOVEL CLASS OF NON-BETA-LACTAM PBP INHIBITORS
READ MOREFollowing the integration of Mutabilis’ second programme in ENABLE in April 2018, the ENABLE Portfolio Management Committee has selected a candidate from this programme.
READ MOREMutabilis will be represented at the ASM MICROBE 2019 conference in San-Francisco from June 20th to 24th 2019.
READ MORELike last year, Mutabilis delegates will participate to the Berlin Conference on Novel Antimicrobials and Diagnosstics 2019 on March 14th – 15th 2019.
READ MOREThe World Health Organization had published earlier this year a list of the most concerning pathogens. The WHO continues with a report on the pipeline of antibiotics currently in clinical development to assess how we are going to manage the pathogens of the list.
READ MORE